预约演示

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

2024-03-26

临床结果免疫疗法临床2期

- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment

SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit's AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for Cancer Research (AACR).

Lunit's AI-powered analzyer for quantitative immune phenotyping from H&E, "Lunit SCOPE IO"

Lunity researchers of Yonsei Cancer Hospital Head and Neck Cancer CenH&E DeLunitent of Oncology (Prof. Hye Ryun Kim, Min Hee Hong, Chang Gon Kim, Hyun Wook Kim), Department of Otolaryngology (Prof. Yoon Woo Koh, Da hee Kim), and Department of Pathology (Prof. Sun Och Yoon) from Yonsei University College of Medicine, Seoul, Korea, the study focuses on the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma (HNSCC) patients. This investigation addresses the current lack of exploration into the clinical implications of neoadjuvant immunotherapy in HNSCC patients with resectable tumors, utilizing Lunit SCOPE IO to examine the changes in tumor microenvironment when treated with durvalumab and tremelimumab.

In this phase II randoYonsei Cancer Hospital Head and Neck Cancer Center Cancerl trial, 4Head and Neck Cancere enrolled, with 24 receiving preoperative durvalumab and 24 receiving a combination of durvalumab plus tremelimumab before surgical resection. Both treatment groups demonstrated favorable safety profiles, affirminYonsei University College of Medicineunotherapy in resectable HNSCC without causing delays in surgery.head and neck squamous cell carcinoma (HNSCC)HNSCC resectable tumors tumor durvalumab tremelimumab

The study findings revealed that patients treatHNSCCth the combination of durvalumab and tremelimumab exhibidurvalumabicantly better 4-year distant recurdurvalumab survitremelimumabompared to those receiving durvalumab monotherapy (91.1% vs. 53.3%), suggesting the potential benefits of combining durvalumab with tremelimumab in iresectable HNSCC outcomes. Similarly, the 4-year overall survival (OS) was notably higher in patients receiving combination therapy (83.1% vs. 67.5%). Additionally, Lunit SCOPE IO's AI analysis backed the remarkable shift in the tumor microenvironment towards an inflamed phenotype, characterized by increased immune activity within the tumor area, in patients receiving combination therapy. This was in contrast to those treated with durvalumab monotherapy or cytotoxic chemotherapy.

Moreover, analysis of circulating immune cells revealed that patients recedurvalumab durvtremelimumabremelimumab showed increased activity and proliferation of certain immune cells, indicating a unique immunedurvalumabinduced by the combination therapy compared to durvalumab alone.durvalumab tremelimumab tumor tumor durvalumab

"Through this prospective clinical study, we have confirmed the clinical utility of pdurvalumabe immtremelimumabor treating locally advanced head and neck cancer," said Professor Kim Hye Ryun, head of the research. "This discovery has the potential to revolutionizedurvalumabeatment paradigms and significantly enhance patient outcomes. We are committed to offering this promising treatment method."

"In this study, Lunit SCOPE IO provides deeper insights into the tumor microenvironment and immune response, empowering heallocally advanced head and neck cancerinformation to make more informed treatment decisions. Additionally, the study addresses a longstanding gap in our understanding of the clinical effectiveness of neoadjuvant immunotherapy in HNSCC, which is the seventh most common cancer worldwide," said Brandon Suh, CEO of Lunit. "Moving forward, Lunit will continue to innovate and enhance Lunit SCOPE's capabilities to further improve patient outcomes and revolutionize personalized cancer treatment through AI."

This study underLunits the importance of leveraging AI technologytumorh as Lunit SCOPE IO, in understanding the complex interplay between the immune system and cancer, ultimately leading to more effective treatment approaches and improved patient outcomes.HNSCC cancer Lunit Lunit Lunit cancer

About Lunitcancer

FoundeLunit2013, Lunit is a deep learning-based medical AI company on a mission to conquer cancer. We are committed to harnessing AI to ensure accurate diagnosis and optimal treatment for each cancer patient using AI-powered medical image analytics and AI biomarkers.

As a medical AI cLunity grounded on clinical evidence, our findings are presented in major cancereviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, and glcanceronferences, including ASCO and RSNA.

After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io.

About Lunit SCOPFDA Lunit Lunit

Lunit Lunit SCOPEsuite of AI-powered software that analyzes tissue slide images for digital pathology and AI biomarker development, aiming to optimize workflow and facilitate more accurate and predictive clinical data for clinicians and researchers.

Lunit SCOPE platform offers multiple AI-powered tissue analysis products and assays that can streamline digital pathology workflow and diagnostics and enhance the drug development process.

Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.

SOURCE Lunittumor PD-L1 HER2 ER PR